Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × vandetanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Carcinoma, Medullary 14 Neoplasm Metastasis 12 Lung Neoplasms 12 Thyroid Neoplasms 8 Breast Neoplasms 6 Neoplasms 5 Glioblastoma 5 Prostatic Neoplasms 4 Gliosarcoma 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Pancreatic Neoplasms 3 Carcinoma, Renal Cell 3 Brain Neoplasms 3 Adenocarcinoma 3 Thyroid Cancer, Papillary 2 Recurrence 2 Ovarian Neoplasms 2 Kidney Neoplasms 2 Head and Neck Neoplasms 2 Familial medullary thyroid carcinoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Biliary Tract Neoplasms 2 Adenocarcinoma, Follicular 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1

Interventions

Fulvestrant 16 Letrozole 8 Anastrozole 7 Capecitabine 5 olaparib 4 Docetaxel 4 pyrotinib 3 palbociclib 3 Vinorelbine 3 Goserelin 3 Aromatase Inhibitors 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 exemestane 2 dalpiciclib 2 Trastuzumab 2 Paclitaxel 2 FCN-437c 2 Dasatinib 2 Alpelisib 2 vandetanib 1 talazoparib 1 sonidegib 1 neratinib 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 entinostat 1 elacestrant 1 disitamab vedotin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed

64 enrolled 7 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡